241 related articles for article (PubMed ID: 32082489)
1. Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas.
Lopez S; Perrone E; Bellone S; Bonazzoli E; Zeybek B; Han C; Tymon-Rosario J; Altwerger G; Menderes G; Bianchi A; Zammataro L; Manzano A; Manara P; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Raspagliesi F; Angioli R; Buza N; Hui P; Bond HM; Santin AD
Oncotarget; 2020 Feb; 11(5):560-570. PubMed ID: 32082489
[TBL] [Abstract][Full Text] [Related]
2. Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo.
Perrone E; Manara P; Lopez S; Bellone S; Bonazzoli E; Manzano A; Zammataro L; Bianchi A; Zeybek B; Buza N; Tymon-Rosario J; Altwerger G; Han C; Menderes G; Huang GS; Ratner E; Silasi DA; Azodi M; Hui P; Schwartz PE; Scambia G; Santin AD
Mol Oncol; 2020 Mar; 14(3):645-656. PubMed ID: 31891442
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma.
Han C; Perrone E; Zeybek B; Bellone S; Tymon-Rosario J; Altwerger G; Menderes G; Feinberg J; Haines K; Muller Karger ME; Bianchi A; Zammataro L; Manzano A; Bonazzoli E; Manara P; Buza N; Hui P; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Lopez S; Santin AD
Gynecol Oncol; 2020 Feb; 156(2):430-438. PubMed ID: 31839338
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer.
Perrone E; Lopez S; Zeybek B; Bellone S; Bonazzoli E; Pelligra S; Zammataro L; Manzano A; Manara P; Bianchi A; Buza N; Tymon-Rosario J; Altwerger G; Han C; Menderes G; Ratner E; Silasi DA; Azodi M; Hui P; Schwartz PE; Scambia G; Santin AD
Front Oncol; 2020; 10():118. PubMed ID: 32117765
[No Abstract] [Full Text] [Related]
5. Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan.
Zeybek B; Manzano A; Bianchi A; Bonazzoli E; Bellone S; Buza N; Hui P; Lopez S; Perrone E; Manara P; Zammataro L; Altwerger G; Han C; Tymon-Rosario J; Menderes G; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin A
Sci Rep; 2020 Jan; 10(1):973. PubMed ID: 31969666
[TBL] [Abstract][Full Text] [Related]
6. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers.
Cardillo TM; Govindan SV; Sharkey RM; Trisal P; Arrojo R; Liu D; Rossi EA; Chang CH; Goldenberg DM
Bioconjug Chem; 2015 May; 26(5):919-31. PubMed ID: 25915780
[TBL] [Abstract][Full Text] [Related]
7. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.
Ocean AJ; Starodub AN; Bardia A; Vahdat LT; Isakoff SJ; Guarino M; Messersmith WA; Picozzi VJ; Mayer IA; Wegener WA; Maliakal P; Govindan SV; Sharkey RM; Goldenberg DM
Cancer; 2017 Oct; 123(19):3843-3854. PubMed ID: 28558150
[TBL] [Abstract][Full Text] [Related]
8. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan.
Goldenberg DM; Sharkey RM
MAbs; 2019; 11(6):987-995. PubMed ID: 31208270
[TBL] [Abstract][Full Text] [Related]
9. Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer.
Cardillo TM; Rossi DL; Zalath MB; Liu D; Arrojo R; Sharkey RM; Chang CH; Goldenberg DM
Oncotarget; 2020 Oct; 11(43):3849-3862. PubMed ID: 33196706
[TBL] [Abstract][Full Text] [Related]
10. Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon.
Furlanetto J; Marmé F; Loibl S
Future Oncol; 2022 Sep; 18(28):3199-3215. PubMed ID: 36069628
[TBL] [Abstract][Full Text] [Related]
11. Tackling metastatic triple-negative breast cancer with sacituzumab govitecan.
Schreiber AR; Andress M; Diamond JR
Expert Rev Anticancer Ther; 2021 Dec; 21(12):1303-1311. PubMed ID: 34651524
[No Abstract] [Full Text] [Related]
12. Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report.
Han C; Bellone S; Schwartz PE; Govindan SV; Sharkey RM; Goldenberg DM; Santin AD
Gynecol Oncol Rep; 2018 Aug; 25():37-40. PubMed ID: 29977989
[TBL] [Abstract][Full Text] [Related]
13. Sacituzumab govitecan for hormone receptor-positive and triple-negative breast cancers.
Satti SA; Sheikh MS
Mol Cell Pharmacol; 2023; 15(1):1-5. PubMed ID: 37090944
[TBL] [Abstract][Full Text] [Related]
14. Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors.
Fenn KM; Kalinsky K
Drugs Today (Barc); 2019 Sep; 55(9):575-585. PubMed ID: 31584574
[TBL] [Abstract][Full Text] [Related]
15. Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer.
Shastry M; Jacob S; Rugo HS; Hamilton E
Breast; 2022 Dec; 66():169-177. PubMed ID: 36302269
[TBL] [Abstract][Full Text] [Related]
16. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.
Bardia A; Tolaney SM; Punie K; Loirat D; Oliveira M; Kalinsky K; Zelnak A; Aftimos P; Dalenc F; Sardesai S; Hamilton E; Sharma P; Recalde S; Gil EC; Traina T; O'Shaughnessy J; Cortes J; Tsai M; Vahdat L; Diéras V; Carey LA; Rugo HS; Goldenberg DM; Hong Q; Olivo M; Itri LM; Hurvitz SA
Ann Oncol; 2021 Sep; 32(9):1148-1156. PubMed ID: 34116144
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.
Bardia A; Mayer IA; Diamond JR; Moroose RL; Isakoff SJ; Starodub AN; Shah NC; O'Shaughnessy J; Kalinsky K; Guarino M; Abramson V; Juric D; Tolaney SM; Berlin J; Messersmith WA; Ocean AJ; Wegener WA; Maliakal P; Sharkey RM; Govindan SV; Goldenberg DM; Vahdat LT
J Clin Oncol; 2017 Jul; 35(19):2141-2148. PubMed ID: 28291390
[TBL] [Abstract][Full Text] [Related]
18. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).
Goldenberg DM; Cardillo TM; Govindan SV; Rossi EA; Sharkey RM
Oncotarget; 2015 Sep; 6(26):22496-512. PubMed ID: 26101915
[TBL] [Abstract][Full Text] [Related]
19. Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan).
Sharkey RM; McBride WJ; Cardillo TM; Govindan SV; Wang Y; Rossi EA; Chang CH; Goldenberg DM
Clin Cancer Res; 2015 Nov; 21(22):5131-8. PubMed ID: 26106073
[TBL] [Abstract][Full Text] [Related]
20. Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer.
Weiss J; Glode A; Messersmith WA; Diamond J
Expert Rev Anticancer Ther; 2019 Aug; 19(8):673-679. PubMed ID: 31398063
[No Abstract] [Full Text] [Related]
[Next] [New Search]
